# Allogene Therapeutics (ALLO) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ALLO
## Company Profile
- Ticker: ALLO
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: CAR-T Therapy
## Stock Data
- Close: 2.07 USD
- Market cap: 707566850.05 USD
- Last updated: 2026-08-12
## Business Overview
### Allogeneic CAR T Company
Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing.
### Cema-Cel
Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for outpatient administration. It has received FDA Regenerative Medicine Advanced Therapy and Fast Track designations in first-line large B-cell lymphoma consolidation.
### MRD-Guided Lymphoma Treatment
The pivotal Phase 2 ALPHA3 study evaluates cema-cel in first-line large B-cell lymphoma patients who remain minimal residual disease-positive after standard treatment. This approach seeks to intervene before overt clinical relapse.
### ALLO-329
ALLO-329 is a dual-targeting CD19/CD70 AlloCAR T candidate for autoimmune diseases. Its Dagger technology is designed to reduce host rejection and potentially limit dependence on conventional chemotherapy-based lymphodepletion.
## Why The Stock Is Moving

The latest monitored company update is “Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Clinical and translational data from the Phase 1 RESOLUTION study of ALLO-329 in the fourth quarter of 2026.
- Interim event-free-survival update from the pivotal Phase 2 ALPHA3 study in mid-2027.
- Completion of ALPHA3 enrollment by the end of 2027.

## Recent News
- 2026-08-12 20:05 EST — [Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-reports-second-quarter-2026-financial-results-and-business-0fe2afc4) — Source: Allogene Therapeutics
- 2026-08-04 12:30 EST — [Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-to-report-second-quarter-2026-financial-results-and-provid-8d513331) — Source: Allogene Therapeutics
- 2026-07-29 12:30 EST — [Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-d-70ba2236) — Source: Allogene Therapeutics
- 2026-07-15 12:30 EST — [Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-journal-of-clinical-oncology-publication-of-phas-905efc2b) — Source: Allogene Therapeutics
- 2026-05-28 21:02 EST — [Allogene Therapeutics Announces Planned CEO Succession](https://biopharmsignal.com/news/ALLO/allogene-therapeutics-announces-planned-ceo-succession) — Source: Allogene Therapeutics